Abstract
e14576 Background: Survival from mCRC has improved over the last decade, in part due to access to biological agents. In Australia, the first VEGF and EGFR inhibitors were approved for subsidisation...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
